UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

Shares of UCB SA (OTCMKTS:UCBJF) gapped down before the market opened on Monday . The stock had previously closed at $305.3625, but opened at $294.35. UCB shares last traded at $294.35, with a volume of 3 shares traded.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Stephens reissued an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a report on Monday, February 16th. Wolfe Research began coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating for the company. Barclays restated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a report on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy”.

UCB Trading Down 3.6%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average is $310.27 and its 200-day moving average is $292.41.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.